IceCure Medical (ICCM) said Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its cryogenic system connector invention.
The notice follows grants for the same patent in the US, Europe, and Japan, the company said.
The company said its novel cryogenic pump is submersible in liquid nitrogen and is designed to be used for multiple procedures or longer duration procedures without the need to refill.
IceCure said it develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing, as an alternative to surgical tumor removal.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。